Wealthfront Advisers
AQST icon

Wealthfront Advisers’s Aquestive Therapeutics AQST Stock Holding History

Wealthfront Advisers’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.4K Sell
10,679
-1,448
-12% -$6.09K ﹤0.01% 1113
2026
Q1 		$50.3K Buy
+12,127
New +$49.2K ﹤0.01% 1063

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Wealthfront Advisers's AQST Position: Q2 2026 in Review

Wealthfront Advisers reduced its Aquestive Therapeutics (AQST) stake by 12% in Q2 2026, selling an estimated $6.09K and leaving 10,679 shares worth $44.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1113.

Wealthfront Advisers first reported a position in AQST in Q1 2026 and has held it in 2 quarters since. The position peaked at $50.3K in Q1 2026. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Wealthfront Advisers held 10,679 shares of Aquestive Therapeutics worth $44.4K as of Q2 2026.
  • Wealthfront Advisers sold 1,448 Aquestive Therapeutics shares in Q2 2026, an estimated $6.09K.
  • Aquestive Therapeutics made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #1113 holding.
  • Wealthfront Advisers first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Wealthfront Advisers's Aquestive Therapeutics position peaked at $50.3K in Q1 2026.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.